RT Journal Article
T1 Incidence, risk factors, and outcome of chronic rejection during antiviral therapy for posttransplant recurrent hepatitis C
A1 Fernández Vázquez, María Inmaculada
A1 Ulloa, Esperanza
A1 Colina Ruiz-Delgado, Francisco
A1 Abradelo De Usera, Manuel
A1 Jiménez Romero, Luis Carlos
A1 Gimeno, Alberto
A1 Meneu Díaz, Juan Carlos
A1 Lumbreras Bermejo, Carlos Juan
A1 Solís Herruzo, José Antonio
A1 Moreno González, Enrique
AB Antiviral therapy for recurrent hepatitis C in liver transplantation has been associated with the development of chronic rejection. The aim of this study was to assess the incidence, evolution, and risk factors associated with the development of chronic rejection during posttransplant hepatitis C virus antiviral therapy. Seventy-nine patients with posttransplant recurrent hepatitis C who were treated with pegylated interferon and ribavirin were prospectively followed. Liver biopsy was performed before antiviral therapy was initiated and when liver tests worsened during therapy. Pretransplant and posttransplant factors were analyzed as potential risk factors for the development of chronic rejection. Seven of 79 patients (9%) developed chronic rejection during antiviral therapy. The mean time from the start of treatment to the development of chronic rejection was 5.8 months (3–12 months). An analysis of factors associated with the development of chronic rejection showed that the use of cyclosporine as immunosuppression therapy (6 of 19 patients who received cyclosporine developed chronic rejection in comparison with only 1 of 57 patients who received tacrolimus; P = 0.0013), achievement of sustained virological response (P = 0.043), and ribavirin discontinuation (P = 0.027) were associated with the development of chronic rejection. In conclusion, the development of chronic rejection during posttransplant pegylated interferon and ribavirin therapy is a severe complication. The use of cyclosporine, ribavirin discontinuation, and viral infection elimination seem to be associated with the development of this complication. Liver Transpl 15:948–955, 2009. © 2009 AASLD.
PB Wiley
SN 1527-6465
YR 2009
FD 2009-07-29
LK https://hdl.handle.net/20.500.14352/114124
UL https://hdl.handle.net/20.500.14352/114124
LA eng
NO Fernández I, Ulloa E, Colina F, Abradelo M, Jiménez C, Gimeno A, Meneu JC, Lumbreras C, Solís-Herruzo JA, Moreno E. Incidence, risk factors, and outcome of chronic rejection during antiviral therapy for posttransplant recurrent hepatitis C. Liver Transpl. 2009 Aug;15(8):948-55. doi: 10.1002/lt.21780
DS Docta Complutense
RD 16 dic 2025